(18)F-FDG PET-CT for Surveillance of Brazilian Patients with Li-Fraumeni Syndrome.
OBJECTIVE
To evaluate the effectiveness of (18)F-Fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) for detecting early cancer in carriers of germline TP53 mutation, the genetic defect underlying Li-Fraumeni and related syndromes, which predisposes to many forms of cancer throughout life.


METHODS
A total of 30 adult patients from six families with germline TP53 mutations were recruited. These patients did not have a diagnosis of cancer in the 24 months preceding the study. Anomalous concentrations from whole-body (18)F-FDG-PET/CT were assessed by two independent experts. Suspicious lesions were excised and subjected to pathological examination.


RESULTS
A total of 6/30 patients showed abnormal (18)F-FDG-concentration. Confirmation studies revealed three cases of cancer, including one lung cancer, one ovarian cancer, and one disseminated breast cancer. Three patients had non-malignant lesions (one Bartholin's cyst and two cases of reactive lymph nodes).


CONCLUSIONS
(18)F-FDG-PET/CT is effective in detecting cancer in subjects who are asymptomatic according to current screening guidelines. These results further suggest that (18)F-FDG-PET/CT is an appropriate method for surveillance of cancer risk in TP53 mutation carriers.
Oncogenetics, AC Camargo Cancer Center , São Paulo , Brazil.
Sonia Tereza Santos
ST
Nogueira
Nuclear Medicine, AC Camargo Cancer Center , São Paulo , Brazil.
Eduardo Nóbrega Pereira
EN
Lima
Oncogenetics, AC Camargo Cancer Center , São Paulo , Brazil.
Amanda França
AF
Nóbrega
Nuclear Medicine, AC Camargo Cancer Center , São Paulo , Brazil.
Ivone Do Carmo Gonçalves
Ido C
Torres
Nuclear Medicine, AC Camargo Cancer Center , São Paulo , Brazil.
Marcelo
M
Cavicchioli
International Prevention Research Institute (iPRI) , Lyon , France.
Pierre
P
Hainaut
Oncogenetics, AC Camargo Cancer Center , São Paulo , Brazil.
Maria Isabel Waddington
MI
Achatz
Li-Fraumeni; PET-CT; oncogenetic; p.R337H; screening